美国 · 平台与数据 · MarketBeat
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride,…
在 MarketBeat 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)
